Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancerUgo De Giorgi, Vicente Valero, Eric Rohren, et al.
Cancer Cell International|December 24, 2025
Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancerNadia Bayou, Sarah Henretta, Laura Munoz-Arcos, et al.
Breast Cancer Research : BCR|January 10, 2015
Circulating tumor cells in newly diagnosed inflammatory breast cancerMichal Mego, Antonio Giordano, Ugo De Giorgi, et al.
Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.
Biorxiv : the Preprint Server for Biology|May 13, 2026
A tumor metabolism-angiogenesis-immune axis governs immunotherapy responsesInna Serganova, Giorgia Colombo, Francesco Ballesio, et al.
Frontiers in Oncology|July 3, 2020
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast CancerDouglas K Marks, Robyn D Gartrell, Margueritta El Asmar, et al.
Elife|July 16, 2020
Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531CheukMan C Au, John B Furness, Kara Britt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II StudySara M Tolaney, Kevin Kalinsky, Virginia G Kaklamani, et al.
European Journal of Radiology|October 18, 2024
[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastasesJana Ivanidze, Arman Sharbatdaran, Aliah McCalla, et al.
NPJ Breast Cancer|August 16, 2025
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysisLetizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, et al.
Pageof 5